Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

This project is part of the EDCTP3 programme supported by the European Union

SAFIRE impact

Who will benefit

Who will benefit from the results of the SAFIRE project?

  1. Pregnant women in their first trimester with uncomplicated malaria and their babies, as well as women of childbearing potential with unknown pregnancy status.
  2. Healthcare professionals and drug prescribers/dispensers providing care and treatment for pregnant women and those of childbearing age who could be pregnant.
  3. Policymakers, including the WHO Global Malaria Programme and National Malaria Control Programmes in endemic countries.
  4. The scientific community involved in the fields of malaria, drug safety in pregnancy and trial methodology.

Leveraging SAFIRE project results

How will the successful dissemination and exploitation of SAFIRE project results impact the target group?

  1. The SAFIRE project will support the widespread adoption of research results into national and international malaria treatment guidelines for pregnant women.
  2. The uptake of research results into clinical practice will give pregnant women in sub-Saharan Africa the best medicines to prevent adverse pregnancy outcomes and deaths, in a timely manner.
  3. Clinicians and researchers in sub-Saharan Africa will have the capacity to design and implement adaptive platform trials, and work alongside ethics committees, regulators and policymakers.

Expected outcomes

What are the expected wider scientific, economic and societal outcomes of the project?

  1. Support the achievement of the UN Sustainable Development Goal 3, ‘Ensure healthy lives and promote well-being for all at all ages’ in malaria-endemic countries through the effective treatment of the disease in the first trimester of pregnancy.
  2. Advance the 2030 Malaria Global Technical Strategy through the development of evidence-informed health policies and guidelines within public health systems in sub-Saharan Africa and at the international level.
  3. Contribute to reducing preventable morbidity and mortality associated with malaria in pregnancy, benefiting not only women in the first trimester, but also their unborn babies, women with unknown pregnancy status and the wider community.
  4. Enhance operational capability to rapidly assess new antimalarial treatments in pregnancy.
  5. Support the growth of sustainable networks of clinical sites that can undertake research in early pregnancy in sub-Saharan Africa.
  6. Mitigate socioeconomic setbacks caused by malaria infection in early pregnancy by ensuring widespread access to effective treatment.